The phase II/III trial GRAALL-2014 builds on GRAALL-2003 and 2005 and investigates the acute lymphoblastic leukemia (ALL) of the T and B line. This kind of cancer is a disease of the white blood cells that causes them to spawn uncontrollably. Sickened white blood cells carry an increased amount of leukemia cells (that cause the spawning) and are found in the bone marrow and sometimes in the blood. Normal blood components are suppressed through this process.
GRAALL-2014 is divided into three sub-trials: ALL of the B and T line and of the Philadelphia-positive form (Ph+). Each group identifies the existence of a certain gene at the time of the diagnosis.
GRAALL-2014/B and GRAALL-2014/T aim at improving tolerance and outcome of the chemotherapy. This goal will be achieved by adjusting the therapy for ALL of the B and T line to the age of the patients and characteristics of the disease.
GRAAPH-2014 aims at improving the outcome of the chemotherapy in combination with tyrosine kinase inhibitors (TKI) for Ph+ALL. Tyrosine kinase inhibitors block the enzyme of the tyrosine kinase that would cause leukemia cells to multiply uncontrollably. The drug TKI Nilotinib (Tasigna®) might allow for a reduced dosage of the standard chemotherapy.